Value Dossier Icon

Pharmabarometer Update

Have a look at our latest update of German price negotiations for drugs that went through the AMNOG benefit assessment. The mean price decrease after negotiations was 28 % for all analysed products, 23 % for orphan drugs and 30 % for non-orphan drugs. If you have any further questions or suggestions, please feel free

2022-08-23T09:27:36+02:0023. August 2022|Reimbursement|0 Comments

GKV-FinStG draft law: The status of the comparator will impact the outcome of price negotiations

Recently, the German Federal Ministry of Health has published a draft law on the financial stabilization of the statutory health insurance (GKV-FinStG). In the following figure, we have summarized the newly proposed negotiation terms. The draft law intends for a stricter regulation of price negotiations following benefit assessments depending on the status of the most

Go to Top